The Medical Letter on Drugs and Therapeutics
Acetaminophen Safety - Deja Vu
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it. The text below is reprinted verbatim from The Medical Letter 2002; 44:91. The table that follows on the next page is current.

Acetaminophen Safety [2002]

An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen.1

ANALGESIC EFFECTIVENESS — Mild to moderate pain often responds to two regular strength 325-mg tablets of acetaminophen. A recent meta-analysis found that 1000 mg of acetaminophen (2 extra-strength 500-mg tablets) was somewhat more effective than 600-650 mg in treating moderate to severe postoperative pain, mainly after oral, gynecologic or orthopedic surgery.2 There are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Acetaminophen Safety - Deja Vu
Article code: 1316a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian